Presentation is loading. Please wait.

Presentation is loading. Please wait.

Phase II study of induction chemotherapy with docetaxel, cisplatin, 5-fluorouracil followed by radioimmunotherapy with cetuximab and intensity-modulated.

Similar presentations


Presentation on theme: "Phase II study of induction chemotherapy with docetaxel, cisplatin, 5-fluorouracil followed by radioimmunotherapy with cetuximab and intensity-modulated."— Presentation transcript:

1 Phase II study of induction chemotherapy with docetaxel, cisplatin, 5-fluorouracil followed by radioimmunotherapy with cetuximab and intensity-modulated radiotherapy in combination with a carbon ion boost for locally advanced tumors of the oro-, hypopharynx and larynx  H. Hauswald, A.D. Jensen, J. Krauss, R. Haselmann, K. Lossner, S. Hartmann, C. Windemuth-Kieselbach, M.W. Münter, J. Debus  Clinical and Translational Radiation Oncology  Volume 13, Pages (November 2018) DOI: /j.ctro Copyright © 2018 The Authors Terms and Conditions

2 Fig. 1 Flow-chart of the TPF-C-HIT trial.
Clinical and Translational Radiation Oncology  , 64-73DOI: ( /j.ctro ) Copyright © 2018 The Authors Terms and Conditions

3 Fig. 2 EORTC-QLQ-C30 Questionnaire functional results (mean values) at baseline, last cycle of TPF, last week of therapy, 6 weeks post therapy, 1. Follow-up (3 months), 2. Follow-up (6 months), 3. Follow-up (9 months) and 4. Follow-up (12 months). Clinical and Translational Radiation Oncology  , 64-73DOI: ( /j.ctro ) Copyright © 2018 The Authors Terms and Conditions

4 Fig. 3a EORTC-QLQ-C30 Questionnaire gastrointestinal symptom scales (mean values) at baseline, last cycle of TPF, last week of therapy, 6 weeks post therapy, 1. Follow-up (3 months), 2. Follow-up (6 months), 3. Follow-up (9 months) and 4. Follow-up (12 months). Clinical and Translational Radiation Oncology  , 64-73DOI: ( /j.ctro ) Copyright © 2018 The Authors Terms and Conditions

5 Fig. 3b EORTC-QLQ-C30 Questionnaire non-gastrointestinal symptom scales (mean values) at baseline, last cycle of TPF, last week of therapy, 6 weeks post therapy, 1. Follow-up (3 months), 2. Follow-up (6 months), 3. Follow-up (9 months) and 4. Follow-up (12 months). Clinical and Translational Radiation Oncology  , 64-73DOI: ( /j.ctro ) Copyright © 2018 The Authors Terms and Conditions

6 Fig. 4a EORTC QLQ H&N 35 single item scale scores (oral part, mean values) at baseline, last cycle of TPF, last week of therapy, 6 weeks post therapy, 1. Follow-up (3 months), 2. Follow-up (6 months), 3. Follow-up (9 months) and 4. Follow-up (12 months). Clinical and Translational Radiation Oncology  , 64-73DOI: ( /j.ctro ) Copyright © 2018 The Authors Terms and Conditions

7 Fig. 4b EORTC QLQ H&N 35 single item scale scores (gastrointestinal, mean values) at baseline, last cycle of TPF, last week of therapy, 6 weeks post therapy, 1. Follow-up (3 months), 2. Follow-up (6 months), 3. Follow-up (9 months) and 4. Follow-up (12 months). Clinical and Translational Radiation Oncology  , 64-73DOI: ( /j.ctro ) Copyright © 2018 The Authors Terms and Conditions

8 Fig. 4c EORTC QLQ H&N 35 single item scale scores (other symptoms, mean values) at baseline, last cycle of TPF, last week of therapy, 6 weeks post therapy, 1. Follow-up (3 months), 2. Follow-up (6 months), 3. Follow-up (9 months) and 4. Follow-up (12 months). Clinical and Translational Radiation Oncology  , 64-73DOI: ( /j.ctro ) Copyright © 2018 The Authors Terms and Conditions


Download ppt "Phase II study of induction chemotherapy with docetaxel, cisplatin, 5-fluorouracil followed by radioimmunotherapy with cetuximab and intensity-modulated."

Similar presentations


Ads by Google